TY - JOUR AU - von Minckwitz, G. AU - Harder, S. AU - Hövelmann, S. AU - Jäger, E. AU - Al-Batran, S. -. E. AU - Loibl, S. AU - Atmaca, A. AU - Cimpoiasu, C. AU - Neumann, A. AU - Abera, A. PY - 2005 DA - 2005// TI - Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas JO - Breast Cancer Res VL - 7 UR - https://doi.org/10.1186/bcr1264 DO - 10.1186/bcr1264 ID - von Minckwitz2005 ER - TY - JOUR AU - Wels, W. AU - Harwerth, I. M. AU - Mueller, M. AU - Groner, B. AU - Hynes, N. E. PY - 1992 DA - 1992// TI - Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor JO - Cancer Res VL - 52 ID - Wels1992 ER - TY - JOUR AU - Wels, W. AU - Beerli, R. AU - Hellmann, P. AU - Schmidt, M. AU - Marte, B. M. AU - Kornilova, E. S. AU - Hekele, A. AU - Mendelsohn, J. AU - Groner, B. AU - Hynes, N. E. PY - 1995 DA - 1995// TI - EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins JO - Int J Cancer VL - 60 UR - https://doi.org/10.1002/ijc.2910600120 DO - 10.1002/ijc.2910600120 ID - Wels1995 ER - TY - CHAP AU - Ehrlich, P. ED - Himmelweit, F. ED - Marquardt, M. ED - Dale, H. PY - 1956 DA - 1956// TI - The relationship between chemical constitution, distribution, and pharmacological action BT - The Collected Papers of Paul Ehrlich PB - Pergamon Press CY - Elmsford, NY ID - Ehrlich1956 ER - TY - JOUR AU - Slamon, D. J. AU - Godolphin, W. AU - Jones, L. A. AU - Holt, J. A. AU - Wong, S. G. AU - Keith, D. E. AU - Levin, W. J. AU - Stuart, S. G. AU - Udove, J. AU - Ullrich, A. PY - 1989 DA - 1989// TI - Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer JO - Science VL - 244 UR - https://doi.org/10.1126/science.2470152 DO - 10.1126/science.2470152 ID - Slamon1989 ER - TY - JOUR AU - Schneider, P. M. AU - Hung, M. C. AU - Chiocca, S. M. AU - Manning, J. AU - Zhao, X. Y. AU - Fang, K. AU - Roth, J. A. PY - 1989 DA - 1989// TI - Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer JO - Cancer Res VL - 49 ID - Schneider1989 ER - TY - JOUR AU - Park, J. B. AU - Rhim, J. S. AU - Park, S. C. AU - Kimm, S. W. AU - Kraus, M. H. PY - 1989 DA - 1989// TI - Amplification, overexpression, and rearrangement of the erbB-2 protoonco-gene in primary human stomach carcinomas JO - Cancer Res VL - 49 ID - Park1989 ER - TY - JOUR AU - Slamon, D. J. AU - Leyland-Jones, B. AU - Shak, S. AU - Fuchs, H. AU - Paton, V. AU - Baja-monde, A. AU - Fleming, T. AU - Eiermann, W. AU - Wolter, J. AU - Pegram, M. PY - 2001 DA - 2001// TI - Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 JO - N Engl J Med VL - 344 UR - https://doi.org/10.1056/NEJM200103153441101 DO - 10.1056/NEJM200103153441101 ID - Slamon2001 ER - TY - JOUR AU - Vogel, C. L. AU - Cobleigh, M. A. AU - Tripathy, D. AU - Gutheil, J. C. AU - Harris, L. N. AU - Fehrenbacher, L. AU - Slamon, D. J. AU - Murphy, M. AU - Novotny, W. F. AU - Burchmore, M. PY - 2002 DA - 2002// TI - Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.20.3.719 DO - 10.1200/JCO.2002.20.3.719 ID - Vogel2002 ER - TY - JOUR AU - Hinoda, Y. AU - Sasaki, S. AU - Ishida, T. AU - Imai, K. PY - 2004 DA - 2004// TI - Monoclonal antibodies as effective therapeutic agents for solid tumors JO - Cancer Sci VL - 95 UR - https://doi.org/10.1111/j.1349-7006.2004.tb03319.x DO - 10.1111/j.1349-7006.2004.tb03319.x ID - Hinoda2004 ER - TY - JOUR AU - Pegram, M. D. AU - Lipton, A. AU - Hayes, D. F. AU - Weber, B. L. AU - Baselga, J. M. AU - Tripathy, D. AU - Baly, D. AU - Baughman, S. A. AU - Twaddell, T. AU - Glaspy, J. A. PY - 1998 DA - 1998// TI - Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment JO - J Clin Oncol VL - 16 UR - https://doi.org/10.1200/JCO.1998.16.8.2659 DO - 10.1200/JCO.1998.16.8.2659 ID - Pegram1998 ER - TY - JOUR AU - Seidman, A. AU - Hudis, C. AU - Pierri, M. K. AU - Shak, S. AU - Paton, V. AU - Ashby, M. AU - Murphy, M. AU - Stewart, S. J. AU - Keefe, D. PY - 2002 DA - 2002// TI - Cardiac dysfunction in the trastuzumab clinical trials experience JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.20.5.1215 DO - 10.1200/JCO.2002.20.5.1215 ID - Seidman2002 ER - TY - JOUR AU - Arnon, R. AU - Sela, M. PY - 1982 DA - 1982// TI - In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies JO - Immunol Rev VL - 62 UR - https://doi.org/10.1111/j.1600-065X.1982.tb00387.x DO - 10.1111/j.1600-065X.1982.tb00387.x ID - Arnon1982 ER - TY - JOUR AU - Wargalla, U. C. AU - Reisfeld, R. A. PY - 1989 DA - 1989// TI - Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells JO - Proc Natl Acad Sci USA VL - 86 UR - https://doi.org/10.1073/pnas.86.13.5146 DO - 10.1073/pnas.86.13.5146 ID - Wargalla1989 ER - TY - JOUR AU - Siegall, C. B. PY - 1994 DA - 1994// TI - Targeted toxins as anticancer agents JO - Cancer VL - 74 UR - https://doi.org/3.0.CO;2-V DO - 3.0.CO;2-V ID - Siegall1994 ER - TY - JOUR AU - Hall, W. A. AU - Fodstad, O. PY - 1992 DA - 1992// TI - Immunotoxins and central nervous system neoplasia JO - J Neurosurg VL - 76 UR - https://doi.org/10.3171/jns.1992.76.1.0001 DO - 10.3171/jns.1992.76.1.0001 ID - Hall1992 ER - TY - JOUR AU - Pastan, I. PY - 2003 DA - 2003// TI - Immunotoxins containing Pseudomonasexotoxin A: a short history JO - Cancer Immunol Immunother VL - 52 ID - Pastan2003 ER - TY - JOUR AU - Pai-Scherf, L. H. AU - Villa, J. AU - Pearson, D. AU - Watson, T. AU - Liu, E. AU - Willingham, M. C. AU - Pastan, I. PY - 1999 DA - 1999// TI - Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor JO - Clin Cancer Res VL - 5 ID - Pai-Scherf1999 ER - TY - JOUR AU - Azemar, M. AU - Djahansouzi, S. AU - Jager, E. AU - Solbach, C. AU - Schmidt, M. AU - Maurer, A. B. AU - Mross, K. AU - Unger, C. AU - von Minckwitz, G. AU - Dall, P. PY - 2003 DA - 2003// TI - Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2 JO - Breast Cancer Res Treat VL - 82 UR - https://doi.org/10.1023/B:BREA.0000004371.48757.19 DO - 10.1023/B:BREA.0000004371.48757.19 ID - Azemar2003 ER - TY - JOUR AU - Christiansen, J. AU - Rajasekaran, A. K. PY - 2004 DA - 2004// TI - Biological impediments to monoclonal antibody-based cancer immunotherapy JO - Mol Cancer Ther VL - 3 ID - Christiansen2004 ER - TY - JOUR AU - Maurer-Gebhard, M. AU - Schmidt, M. AU - Azemar, M. AU - Altenschmidt, U. AU - Stocklin, E. AU - Wels, W. AU - Groner, B. PY - 1998 DA - 1998// TI - Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells JO - Cancer Res VL - 58 ID - Maurer-Gebhard1998 ER -